Category News

Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

Viatris Reports Positive Top-Line Results from Pivotal Phase 3 VEGA-3 Trial of MR-141 for Presbyopia, Underscoring Its Potential as a Non-Invasive Vision Correction Therapy Viatris, a global healthcare company committed to increasing access to high-quality medicines and health solutions worldwide,…

Read MoreViatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

BeOne Medicines Presents Transformative Oncology Portfolio at Research & Development Day

BeOne Medicines Showcases Bold Vision and Expansive Oncology Pipeline at 2025 R&D Day BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its highly anticipated Research and Development (R&D) Day. The event spotlighted…

Read MoreBeOne Medicines Presents Transformative Oncology Portfolio at Research & Development Day

Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines…

Read MoreMerck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

Biogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data

Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306), an investigational antisense oligonucleotide (ASO) therapy for spinal…

Read MoreBiogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data

Price of World’s First Malaria Vaccine for Children in Endemic Countries Slashed by Over 50%, Now Under $5

Bharat Biotech and GSK Commit to Affordable Access to RTS,S, the World’s First Malaria Vaccine, with Major Price Reduction and Expanded Availability in Africa Bharat Biotech International Limited (BBIL) and GSK plc have jointly announced a pivotal step toward global…

Read MorePrice of World’s First Malaria Vaccine for Children in Endemic Countries Slashed by Over 50%, Now Under $5

Novartis Acquires Regulus Therapeutics, Expanding its RNA-Based Drug Pipeline

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc., a biotechnology firm known for its expertise in microRNA-targeting…

Read MoreNovartis Acquires Regulus Therapeutics, Expanding its RNA-Based Drug Pipeline

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

Revolution Medicines Secures $2 Billion Strategic Funding from Royalty Pharma to Accelerate Development and Global Commercialization of RAS(ON) Inhibitor Portfolio Revolution Medicines, a leading late-stage oncology company focused on precision therapies for genetically defined cancers, has announced a landmark funding…

Read MoreRevolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

Bio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies

Bio-Techne and USP Forge Strategic Alliance to Advance Quality Standards in Monoclonal Antibody and Gene Therapy Development Bio-Techne Corporation, a global life sciences company renowned for its high-performance reagents, instruments, and services, today announced a new distribution agreement with the…

Read MoreBio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies